Rules Navigator

Register

McKinsey OxyContin settlement illustrates need for robust comms surveillance and archiving

Purdue Pharma HQ in downtown Stamford, Connecticut. Purdue Pharma was the maker of OxyContin and a profitable McKinsey client. Photo by Drew Angerer/Getty Images

Thomas Hyrkiel, Julie DiMauro

 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The matter-of-fact narrative is scathing of the moral and ethical void at Purdue as well as the behavior at the consulting firm.

In December we briefly reported on a significant DOJ fine of $650m against McKinsey & Company. This fine was levied as part of a criminal and civil settlement between the consulting firm and the DOJ in relation to the firm’s work with Purdue Pharma on the marketing and sale of

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in
, , , , , , ,
You may also like